SPAC Update – February 17

– ASCA announced a business combination with NewGenIvf, stockholders approved deadline extension to Mar 17, 3.3 million shares (47.4%) redeemed, 3.6 million shares remain, $90k added to trust account
– GWII / Direct Biologics deal terminated
– TWNI announced 32.5 million shares (94.2%) tendered for redemption
– SLAM announced 35.1 million shares (61.0%) tendered for redemption
– OPA filed DEF14a to extend deadline to July 25 2023 + 3 months, vote Mar 17, NAV $10.19
– REVE filed DEF14a to extend deadline to Apr 2 2023, vote Feb 28 (note Feb 24 deal vote), NAV $10.51
– TETC filed DEF14a to extend deadline to Sept 19 2023, vote Mar 16, NAV $10.14, set redemption date as Apr 5 to get around excise tax (2024 fiscal year)
– INAQ filed DEF14a to extend deadline to Apr 7 2023 + 5 months, vote Mar 2, NAV $10.21
– GEEX filed DEF14a to extend deadline to Dec 7 2023, vote Mar 6, NAV $10.43
– TRON filed PRE14a to extend deadline to Mar 21 2024, NAV $10.50
– KSI redemption NAV revised from $10.05 to $10.10
– SPKB filed DEF14a to Extend deadline to June 15 2023 + 9 months, Vote Mar 6, NAV $10.19
– LBBB filed PRE14a To extend deadline to June 11 2023
– PFDR extension vote
– ALOR extension vote
– LFAC amendment vote
– TPBA redemption
– GGAA redemption
– CCAI redemption